A Phase 3 interventional study of Lamotrigine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 63 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.
Among the 36 studies testing lamotrigine in Epilepsy, this one is the 14th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 3, and was the 17th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:
Assiut University
Ages 2–12 · Healthy volunteers
National Taiwan University Hospital
Ages 20+
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 36 interventional studies. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Epilepsy by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 53 finished, 23 (43%) have results posted.
Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 16th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2007, is one of 18 in phase 3, and was the 19th registered.
GlaxoSmithKline’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing lamotrigine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label lamotrigine
Drug: Lamotrigine
Open-label
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.
Time frame: From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)
Percent Change From Baseline (BL) in Weekly Seizure (sz.) Frequency for All Partial Seizures During Each Phase of the Study
Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.
Time frame: Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (Week 30 or 33)
Number of Participants With the Indicated Change From Baseline in Weekly Seizure Frequency During Each Phase of the Study
Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \>=25%, \>=50%, \>=75%, or 100% reduction or a \>=50% increase in percent change from Baseline in weekly seizure frequency.
Time frame: Baseline (Week 0), Dose-Escalation Phase (Week 7), Maintenance Phase (Week 15), Adjunctive Optimization (Adj O) Phase (Week 28), Conversion Phase (Week 20), Monotherapy Phase (Week 28), and end of treatment (ET, Week 30 or 33)
Number of Seizure-free Participants at Baseline Who Remained Seizure-free Throughout the Entire Treatment Period
Participants were considered to be seizure-free if they did not report any seizures at Baseline.
Time frame: Week 30 or 33
Number of Participants With Changes From Baseline in Seizure Severity in the Indicated Categories, as Measured by the Investigator's Global Evaluation (IGE) Scale
Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.
Time frame: Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])
Number of Participants With Changes From Baseline in Overall Clinical Status in the Indicated Categories, as Measured by the IGE Scale
Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.
Time frame: Week 15 (Adjunctive Maintenance [Adj M] Phase), Week 28 (Adjunctive Optimization [Adj O] Phase), Week 28 (Monotherapy [Mono] Phase), and Week 28 (Early Withdrawal [WD])
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points in the Study
Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Change From Baseline in the Height at the Indicated Time Points in the Study
Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Change From Baseline in the Weight at the Indicated Time Points in the Study
Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), Week 28 (WD), and Week 30/33 (End of study [EOS])
Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Percent Change From Baseline in the Basophil, Eosinophil, Hemoglobin, Lymphocyte, Monocyte, Absolute Neutrophil Count, Platelet Count, and White Blood Cell Count at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in the Mean Corpuscle Hemoglobin Concentration (MCHC), Albumin, and Total Protein at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points in the the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\^12 per liter.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Alkaline Phosphatase (Alk P), Alanine Amino Transferase (Ala AT), and Aspartate Amino Transferase (Asp AT) at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Direct Bilirubin (DB), Total Bilirubin (TB), and Creatinine at the Indicated Time Points in the Study
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Change From Baseline in Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Glucose, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.
Time frame: Baseline (Week 0) and Week 15 (Adj M Phase), Week 28 (Adj O Phase), Week 28 (Mono Phase), and Week 28 (WD)
Serum LTG Concentrations at Different LTG Doses Based on the Concomitant AED Groups: Neutral (Without Known Enzyme-inducing AED [EIAED], Valproate [VPA]) With EIAED, and With VPA
The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.
Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28
Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.
Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28
Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.
Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28
Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.
Time frame: Weeks 4, 7, 11, 15, 20, 24, and 28
| Milestone | Lamotrigine (LTG)-Extended Release (XR) Tablets |
|---|---|
| Started | 122 |
| Completed | 84 |
| Not completed | 38 |
| Withdrew: Adverse event | 27 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lack of efficacy | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.
| participants | LTG-XR Tablets |
|---|---|
| Participants with any SAE | 22 |
| Participants with any non-serious AE | 112 |
Partial-onset sz. have a focal site of onset; sz. activity is initially limited to 1 brain hemisphere. Partial sz. can remain simple or complex, or evolve to generalized tonic-clonic sz. Participants (par.) recorded the number of sz., by type as well as the episode duration of innumerable sz. activity), in daily diaries. If par. withdrew from study, data were averaged for the study portion the par. completed up to the time of drug discontinuation. Percent change from BL = (BL value minus study phase value divided by BL value) x 100; positive values indicate reduction from BL in sz. frequency.
| Percent change in seizure frequency | LTG-XR Tablets |
|---|---|
| Dose-Escalation Phase (Week 7), n=55 | 97.8 (-146.3 to 100.0) |
| Maintenance Phase (Week 15), n=43 | 100.0 (-162.5 to 100.0) |
| Adjunctive Optimization Phase (Week 28), n=15 | 100.0 (33.3 to 100.0) |
| Conversion Phase (Week 20), n=24 | 100.0 (-44.5 to 100.0) |
| Monotherapy Phase (Week 28), n=24 | 100.0 (-269.8 to 100.0) |
| End Of Treatment (Week 30/33), n=55 | 90.4 (-86.7 to 100.0) |
Participants recorded the number of seizures, by seizure type, as well as the duration of episodes of innumerable seizure activity in their daily diaries during all phases of the study. For participants who withdrew from the study, seizure data were averaged for the portion of the study the participant completed up to the time of study drug discontinuation. Participants who experienced a change from Baseline in the weekly seizure frequency were categorized as having a \>=25%, \>=50%, \>=75%, or 100% reduction or a \>=50% increase in percent change from Baseline in weekly seizure frequency.
| participants | LTG-XR Tablets |
|---|---|
| Dose-Escalation (Week 7), >=25% reduction, n=55 | 49 |
| Dose-Escalation (Week 7), >=50% reduction, n=55 | 41 |
| Dose-Escalation (Week 7), >=75% reduction, n=55 | 30 |
| Dose-Escalation (Week 7), 100% reduction, n=55 | 27 |
| Dose-Escalation (Week 7), >=50% increase, n=55 | 2 |
| Maintenance (Week 15), >=25% reduction, n=43 | 39 |
| Maintenance (Week 15), >=50% reduction, n=43 | 37 |
| Maintenance (Week 15), >=75% reduction, n=43 | 33 |
| Maintenance (Week 15), 100% reduction, n=43 | 30 |
| Maintenance (Week 15), >=50% increase, n=43 | 2 |
| Adj O (Week 28), >=25% reduction, n=15 | 15 |
| Adj O (Week 28), >=50% reduction, n=15 | 14 |
| Adj O (Week 28), >=75% reduction, n=15 | 12 |
| Adj O (Week 28), 100% reduction, n=15 | 11 |
| Adj O (Week 28), >=50% increase, n=15 | 0 |
| Conversion (Week 20), >=25% reduction, n=24 | 23 |
| Conversion (Week 20), >=50% reduction, n=24 | 23 |
| Conversion (Week 20), >=75% reduction, n=24 | 19 |
| Conversion (Week 20), 100% reduction, n=24 | 17 |
| Conversion (Week 20), >=50% increase, n=24 | 0 |
| Monotherapy (Week 28), >=25% reduction, n=24 | 23 |
| Monotherapy (Week 28), >=50% reduction, n=24 | 20 |
| Monotherapy (Week 28), >=75% reduction, n=24 | 17 |
| Monotherapy (Week 28), 100% reduction, n=24 | 13 |
| Monotherapy (Week 28), >=50% increase, n=24 | 1 |
| ET (Week 30/33), >=25% reduction, n=55 | 47 |
| ET (Week 30/33), >=50% reduction, n=55 | 44 |
| ET (Week 30/33), >=75% reduction, n=55 | 36 |
| ET (Week 30/33), 100% reduction, n=55 | 24 |
| ET (Week 30/33), >=50% increase, n=55 | 1 |
Participants were considered to be seizure-free if they did not report any seizures at Baseline.
| participants | LTG-XR Tablets |
|---|---|
| Remained Seizure-Free | 53 |
| Did Not Remain Seizure-Free | 13 |
Investigators rated the participants' seizure severity at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.
| participants | LTG-XR Tablets |
|---|---|
| Week 15, Adj M Phase, Improvement, n=91 | 36 |
| Week 15, Adj M Phase, No change, n=91 | 54 |
| Week 15, Adj M Phase, Deterioration, n=91 | 1 |
| Week 28, Adj O Phase, Improvement, n=21 | 13 |
| Week 28, Adj O Phase, No change, n=21 | 7 |
| Week 28, Adj O Phase, Deterioration, n=21 | 1 |
| Week 28, Mono Phase, Improvement, n=63 | 29 |
| Week 28, Mono Phase, No change, n=63 | 33 |
| Week 28, Mono Phase, Deterioration, n=63 | 1 |
| Week 28, WD, Improvement, n=35 | 7 |
| Week 28, WD, No change, n=35 | 25 |
| Week 28, WD, Deterioration, n=35 | 3 |
Investigators rated the participants' overall clinical status at Weeks 15 and 28 of the study treatment by using the IGE scale, comprised of 7 categories: 3 for improvement (mild improvement, moderate improvement, and marked improvement), 3 for deterioration (marked deterioration, moderate deterioration, mild deterioration), and 1 for no change. Investigators assessed the degree of the participants' improvement or deterioration or determined whether the participants' condition had not changed compared to their Baseline condition.
| participants | LTG-XR Tablets |
|---|---|
| Week 15, Adj M Phase, Improvement, n=91 | 51 |
| Week 15, Adj M Phase, No change, n=91 | 29 |
| Week 15, Adj M Phase, Deterioration, n=91 | 11 |
| Week 28, Adj O Phase, Improvement, n=21 | 17 |
| Week 28, Adj O Phase, No change, n=21 | 2 |
| Week 28, Adj O Phase, Deterioration, n=21 | 2 |
| Week 28, Mono Phase, Improvement, n=63 | 43 |
| Week 28, Mono Phase, No change, n=63 | 14 |
| Week 28, Mono Phase, Deterioration, n=63 | 6 |
| Week 28, WD, Improvement, n=35 | 7 |
| Week 28, WD, No change, n=35 | 12 |
| Week 28, WD, Deterioration, n=35 | 16 |
Change from Baseline was calculated by subtracting the values of systolic and diastolic blood pressures recorded by the investigator at the indicated time points in the study from the respective Baseline values.
| Millimeters of mercury | LTG-XR Tablets |
|---|---|
| Systolic BP, Week 15, Adj M Phase, n=88 | 1.51 ± 19.038 |
| Systolic BP, Week 28, Adj O Phase, n=21 | -0.62 ± 15.377 |
| Systolic BP, Week 28, Mono Phase, n=63 | 0.68 ± 20.509 |
| Systolic BP, Week 28, WD, n=35 | -4.00 ± 15.566 |
| Systolic BP, Week 30/33, EOS, n=119 | -2.19 ± 15.928 |
| Diastolic BP, Week 15, Adj M Phase, n=88 | -1.22 ± 10.547 |
| Diastolic BP, Week 28, Adj O Phase, n=21 | -1.05 ± 7.214 |
| Diastolic BP, Week 28, Mono Phase, n=63 | -0.08 ± 10.754 |
| Diastolic BP, Week 28, WD, n=35 | -2.09 ± 8.763 |
| Diastolic BP, Week 30/33, EOS, n=119 | -2.07 ± 9.102 |
Change from Baseline was calculated by subtracting the value of height measured by the investigator at the indicated time points in the study from the Baseline value.
| centimeters | LTG-XR Tablets |
|---|---|
| Week 15, Adj M Phase, n=90 | 0.03 ± 1.302 |
| Week 28, Adj O Phase, n=21 | 0.29 ± 2.217 |
| Week 28, Mono Phase, n=62 | -0.03 ± 1.293 |
| Week 28, WD, n=36 | -0.03 ± 1.028 |
| Week 30/33, EOS, n=120 | 0.03 ± 1.417 |
Change from Baseline was calculated by subtracting the value of weight measured by the investigator at the indicated time points in the study from the Baseline value.
| kilograms | LTG-XR Tablets |
|---|---|
| Week 15, Adj M Phase, n=88 | -0.22 ± 3.204 |
| Week 28, Adj O Phase, n=21 | -0.41 ± 2.968 |
| Week 28, Mono Phase, n=62 | -0.48 ± 3.520 |
| Week 28, WD, n=36 | -0.27 ± 3.735 |
| Week 30/33, EOS, n=119 | -0.41 ± 3.470 |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of basophil, eosinophil, hemoglobin, lymphocyte, monocyte, ANC, platelet count, and WBC count at the indicated time points in the study from the Baseline value.
| Giga (10^9) cells per liter | LTG-XR Tablets |
|---|---|
| Basophil, Week 15, Adj M, n=85 | 0.00 (-0.03 to 0.06) |
| Basophil, Week 28, Adj O, n=19 | 0.00 (-0.02 to 0.02) |
| Basophil, Week 28, Mono, n=55 | 0.00 (-0.05 to 0.05) |
| Basophil, Week 28, WD, n=33 | 0.00 (-0.04 to 0.04) |
| Eosinophil, Week 15, Adj M, n=89 | 0.00 (-0.38 to 0.55) |
| Eosinophil, Week 28, Adj O, n=21 | 0.01 (-0.06 to 0.26) |
| Eosinophil, Week 28, Mono, n=61 | 0.01 (-0.23 to 0.54) |
| Eosinophil, Week 28, WD, n=33 | -0.01 (-0.17 to 0.84) |
| Hemoglobin, Week 15, Adj M, n=85 | -4.00 (-38.00 to 19.00) |
| Hemoglobin, Week 28, Adj O, n=19 | -6.00 (-22.00 to 4.00) |
| Hemoglobin, Week 28, Mono, n=55 | -4.00 (-25.00 to 10.00) |
| Hemoglobin, Week 28, WD, n=33 | -2.00 (-21.00 to 31.00) |
| Lymphocytes, Week 15, Adj M, n=85 | -0.12 (-1.55 to 1.52) |
| Lymphocytes, Week 28, Adj O, n=19 | -0.05 (-0.61 to 0.40) |
| Lymphocytes, Week 28, Mono, n=55 | -0.20 (-1.75 to 0.62) |
| Lymphocytes, Week 28, WD, n=33 | -0.09 (-0.94 to 0.66) |
| Monocytes, Week 15, Adj M, n=85 | -0.03 (-0.41 to 0.47) |
| Monocytes, Week 28, Adj O, n=19 | 0.00 (-0.55 to 0.26) |
| Monocytes, Week 28, Mono, n=55 | -0.04 (-0.37 to 0.40) |
| Monocytes, Week 28, WD, n=33 | -0.01 (-0.48 to 0.64) |
| Absolute Neutrophil Count, Week 15, Adj M, n=85 | -0.23 (-3.00 to 5.04) |
| Absolute Neutrophil Count, Week 28, Adj O, n=19 | 0.09 (-2.17 to 3.31) |
| Absolute Neutrophil Count, Week 28, Mono, n=55 | -0.17 (-3.18 to 2.71) |
| Absolute Neutrophil Count, Week 28, WD, n=33 | 0.17 (-1.99 to 6.47) |
| Platelet Count, Week 15, Adj M, n=84 | 1.50 (-91.00 to 226.00) |
| Platelet Count, Week 28, Adj O, n=19 | 3.00 (-55.00 to 216.00) |
| Platelet Count, Week 28, Mono, n=54 | 0.00 (-75.00 to 104.00) |
| Platelet Count, Week 28, WD, n=32 | 6.50 (-80.00 to 172.00) |
| White Blood Cell Count, Week 15, Adj M, n=85 | -0.30 (-2.80 to 5.70) |
| White Blood Cell Count, Week 28, Adj O, n=19 | -0.20 (-2.40 to 3.20) |
| White Blood Cell Count, Week 28, Mono, n=55 | -0.60 (-3.50 to 2.00) |
| White Blood Cell Count, Week 28, WD, n=33 | 0.30 (-2.20 to 6.00) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Percent change from Baseline = (value at each indicated time point in the study minus respective Baseline value divided by Baseline value) x 100.
| Percent change in counts | LTG-XR Tablets |
|---|---|
| Basophil, Week 15, Adj M, n=89 | 0.00 (-0.80 to 1.00) |
| Basophil, Week 28, Adj O, n=21 | 0.00 (-0.50 to 0.50) |
| Basophil, Week 28, Mono, n=61 | 0.00 (-0.80 to 0.90) |
| Basophil, Week 28, WD, n=33 | 0.00 (-0.50 to 0.90) |
| Eosinophil, Week 15, Adj M, n=89 | 0.20 (-4.40 to 10.90) |
| Eosinophil, Week 28, Adj O, n=21 | 0.10 (-1.50 to 4.30) |
| Eosinophil, Week 28, Mono, n=61 | 0.30 (-3.30 to 10.80) |
| Eosinophil, Week 28, WD, n=33 | -0.20 (-2.90 to 17.60) |
| Hematocrit, Week 15, Adj M, n=85 | -0.01 (-0.11 to 0.06) |
| Hematocrit, Week 28, Adj O, n=19 | -0.02 (-0.07 to 0.02) |
| Hematocrit, Week 28, Mono, n=55 | -0.01 (-0.09 to 0.04) |
| Hematocrit, Week 28, WD, n=33 | -0.00 (-0.04 to 0.10) |
| Lymphocytes, Week 15, Adj M, n=89 | -2.10 (-25.80 to 18.90) |
| Lymphocytes, Week 28, Adj O, n=21 | -2.40 (-16.00 to 13.60) |
| Lymphocytes, Week 28, Mono, n=61 | -1.50 (-23.90 to 12.40) |
| Lymphocytes, Week 28, WD, n=33 | -1.60 (-14.20 to 8.10) |
| Monocytes, Week 15, Adj M, n=89 | 0.00 (-8.90 to 6.50) |
| Monocytes, Week 28, Adj O, n=21 | 0.10 (-10.90 to 5.10) |
| Monocytes, Week 28, Mono, n=61 | -0.20 (-6.40 to 9.50) |
| Monocytes, Week 28, WD, n=33 | -0.30 (-8.00 to 8.10) |
| Total Neutrophils, Week 15, Adj M, n=89 | 1.3 (-26.30 to 30.40) |
| Total Neutrophils, Week 28, Adj O, n=21 | 0.50 (-13.80 to 16.80) |
| Total Neutrophils, Week 28, Mono, n=61 | 0.50 (-13.80 to 24.20) |
| Total Neutrophils, Week 28, WD, n=33 | 1.20 (-12.00 to 19.20) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the values of MCHC, albumin, and total protein at the indicated time points in the study from the respective Baseline values.
| grams per liter | LTG-XR Tablets |
|---|---|
| MCHC, Week 15, Adj M, n=85 | -4.00 (-30.00 to 27.00) |
| MCHC, Week 28, Adj O, n=21 | 1.00 (-18.00 to 26.00) |
| MCHC, Week 28, Mono, n=61 | -5.00 (-31.00 to 24.00) |
| MCHC, Week 28, WD, n=33 | 1.00 (-25.00 to 15.00) |
| Albumin, Week 15, Adj M, n=87 | 0.00 (-5.00 to 7.00) |
| Albumin, Week 28, Adj O, n=20 | -1.00 (-8.00 to 3.00) |
| Albumin, Week 28, Mono, n=61 | 0.00 (-6.00 to 6.00) |
| Albumin, Week 28, WD, n=33 | 0.00 (-9.00 to 6.00) |
| Total Protein, Week 15, WD, n=87 | -1.0 (-13.0 to 8.0) |
| Total Protein, Week 28, WD, n=20 | -3.00 (-11.0 to 3.0) |
| Total Protein, Week 28, WD, n=61 | -1.0 (-15.0 to 6.0) |
| Total Protein, Week 28, WD, n=33 | -1.0 (-15.0 to 7.0) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCH at the indicated time points in the study from the Baseline value.
| picograms | LTG-XR Tablets |
|---|---|
| Week 15, Adj M, n=85 | -0.10 (-3.30 to 2.60) |
| Week 28, Adj O, n=19 | 0.10 (-1.20 to 1.60) |
| Week 28, Mono, n=55 | -0.20 (-2.30 to 1.40) |
| Week 28, WD, n=33 | -0.20 (-1.90 to 3.50) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of MCV at the indicated time points in the study from the Baseline value.
| Femtoliters | LTG-XR Tablets |
|---|---|
| Week 15, Adj M, n=85 | 0.00 (-7.00 to 9.00) |
| Week 28, Adj O, n=19 | -1.00 (-7.00 to 5.00) |
| Week 28, Mono, n=55 | 1.00 (-9.00 to 7.00) |
| Week 28, WD, n=33 | 0.00 (-4.00 to 12.00) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of RBC count at the indicated time points in the study from the Baseline value. Change from baseline is measured as the number of red blood cells x 10\^12 per liter.
| Tera (10^12) cells per liter | LTG-XR Tablets |
|---|---|
| Week 15, Adj M, n=85 | -0.10 (-0.90 to 0.40) |
| Week 28, Adj O, n=19 | -0.20 (-0.80 to 0.10) |
| Week 28, Mono, n=55 | -0.10 (-0.70 to 0.40) |
| Week 28, WD, n=33 | 0.00 (-0.50 to 1.00) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of Alk P, Ala AT, and Asp AT at the indicated time points in the study from the Baseline value.
| International units per liter | LTG-XR Tablets |
|---|---|
| Alk P, Week 15, Adj M, n=87 | 1.00 (-86.0 to 141.00) |
| Alk P, Week 28, Adj O, n=20 | -0.50 (-72.0 to 20.0) |
| Alk P, Week 28, Mono, n=61 | -5.0 (-118.0 to 49.0) |
| Alk P, Week 28, WD, n=33 | 2.00 (-90.0 to 90.00) |
| Ala-AT Week 15, Adj M, n=87 | -2.00 (-30.0 to 71.0) |
| Ala-AT, Week 28, Adj O, n=20 | -1.0 (-10.0 to 23.0) |
| Ala-AT, Week 28, Mono, n=61 | -2.0 (-32.0 to 55.0) |
| Ala-AT, Week 28, WD, n=33 | -2.0 (-20.0 to 7.0) |
| Asp-AT, Week 15, Adj M, n=87 | -1.0 (-19.0 to 47.0) |
| Asp-AT, Week 28, WD, n=32 | -3.0 (-34.0 to 7.0) |
| Asp-AT, Week 28, Adj O, n=20 | -2.0 (-13.0 to 18.0) |
| Asp-AT, Week 28, Mono, n=60 | 0.00 (-15.0 to 17.0) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of DB, TB, and creatinine at the indicated time points in the study from the Baseline value.
| micromoles (µmol) per liter | LTG-XR Tablets |
|---|---|
| DB, Week 15, Adj M, n=87 | 0.0 (-1.7 to 6.8) |
| DB, Week 28, Adj O, n=20 | 0.0 (-3.4 to 1.7) |
| DB, Week 28, Mono, n=61 | 0.0 (-1.7 to 12.0) |
| DB, Week 28, WD, n=33 | 0.0 (-1.7 to 1.7) |
| TB, Week 15, Adj M, n=88 | 0.0 (-8.6 to 15.4) |
| TB, Week 28, Adj O, n=20 | 0.0 (-3.4 to 1.7) |
| TB, Week 28, Mono, n=61 | 1.7 (-8.6 to 12.0) |
| TB, Week 28, WD, n=33 | 0.0 (-3.4 to 5.1) |
| Creatinine, Week 15, Adj M, n=88 | 8.8 (-17.7 to 53.0) |
| Creatinine, Week 28, Adj O, n=20 | 8.8 (0.0 to 203.3) |
| Creatinine, Week 28, Mono, n=61 | 8.8 (-17.7 to 53.0) |
| Creatinine, Week 28, WD, n=33 | 0.0 (-17.7 to 17.7) |
The blood samples collected at the study visits were analyzed and assessed at the central laboratory, and the investigator reviewed and assessed the clinical significance. Change from Baseline was calculated by subtracting the value of cholesterol, HDL cholesterol, LDL cholesterol, glucose, potassium, sodium, triglycerides, and urea/BUN at the indicated time points in the study from the Baseline value.
| millimoles (mmol) per liter | LTG-XR Tablets |
|---|---|
| Cholesterol, Week 15, Adj M, n=87 | -0.1 (-1.7 to 1.7) |
| Cholesterol, Week 28, Adj O, n=20 | -0.1 (-2.2 to 0.9) |
| Cholesterol, Week 28, Mono, n=61 | -0.3 (-2.5 to 1.2) |
| Cholesterol, Week 28, WD, n=33 | -0.1 (-3.5 to 1.0) |
| HDL Cholesterol, Week 15, Adj M, n=87 | 0.1 (-1.0 to 0.6) |
| HDL Cholesterol, Week 28, Adj O, n=20 | -0.0 (-0.4 to 0.6) |
| HDL Cholesterol, Week 28, Mono, n=61 | 0.0 (-0.7 to 0.7) |
| HDL Cholesterol, Week 28, WD, n=33 | 0.1 (-0.9 to 0.4) |
| LDL Cholesterol, Week 15, Adj M, n=86 | -0.0 (-1.1 to 1.2) |
| LDL Cholesterol, Week 28, Adj O, n=19 | -0.2 (-1.9 to 1.1) |
| LDL Cholesterol, Week 28, Mono, n=61 | -0.1 (-1.8 to 1.6) |
| LDL Cholesterol, Week 28, WD, n=32 | -0.1 (-0.8 to 1.7) |
| Glucose, Week 15, Adj M, n=87 | -0.1 (-5.8 to 5.3) |
| Glucose, Week 28, Adj O, n=20 | 0.1 (-6.7 to 6.7) |
| Glucose, Week 28, Mono, n=61 | 0.1 (-3.6 to 6.4) |
| Glucose, Week 28, WD, n=33 | 0.3 (-5.2 to 4.2) |
| Potassium, Week 15, Adj M, n=87 | 0.0 (-1.2 to 1.1) |
| Potassium, Week 28, Adj O, n=20 | -0.1 (-0.7 to 1.2) |
| Potassium, Week 28, Mono, n=60 | 0.0 (-1.3 to 1.2) |
| Potassium, Week 28, WD, n=32 | 0.0 (-1.0 to 0.9) |
| Sodium, Week 15, Adj M, n=87 | 0.0 (-4.0 to 6.0) |
| Sodium, Week 28, Adj O, n=20 | 0.5 (-7.0 to 4.0) |
| Sodium, Week 28, Mono, n=61 | -1.0 (-5.0 to 9.0) |
| Sodium, Week 28, WD, n=33 | 1.0 (-3.0 to 7.0) |
| Triglyceride, Week 28, WD, n=87 | -0.3 (-2.3 to 0.9) |
| Triglyceride, Week 28, WD, n=20 | -0.1 (-1.7 to 1.6) |
| Triglyceride, Week 28, WD, n=61 | -0.4 (-1.9 to 1.1) |
| Triglyceride, Week 28, WD, n=33 | 1.0 (-4.6 to 1.1) |
| Urea/BUN, Week 28, WD, n=87 | 0.0 (-10.4 to 5.4) |
| Urea/BUN, Week 28, WD, n=20 | 0.5 (-2.1 to 13.2) |
| Urea/BUN, Week 28, WD, n=61 | 0.0 (-6.4 to 6.8) |
| Urea/BUN, Week 28, WD, n=33 | 0.4 (-4.3 to 3.6) |
The blood samples were collected at the specified study visits; however, serum LTG concentrations were summarized by dose regimen, not by study week. The serum was assayed for LTG using an approved method under the management of Worldwide Bioanalysis, GlaxoSmithKline.
| Micrograms per milliliter | LTG-XR + Neutral | LTG-XR + EIAEDs | LTG-XR + VPA |
|---|---|---|---|
| 12.5 mg, n=0, 0, 1 | NA (NA to NA) | NA (NA to NA) | 0.957 (NA to NA) |
| 25 mg, n=0, 0, 8 | NA (NA to NA) | NA (NA to NA) | 1.362 (0.817 to 2.885) |
| 50 mg, n=30, 2, 8 | 1.281 (0.437 to 3.491) | 0.731 (0.727 to 0.734) | 2.972 (0.937 to 3.553) |
| 100 mg, n=40, 32, 6 | 3.425 (0.717 to 5.825) | 1.165 (0.442 to 4.254) | 4.723 (3.870 to 6.419) |
| 150 mg, n=11, 0, 6 | 5.653 (2.514 to 9.693) | NA (NA to NA) | 6.829 (3.549 to 10.804) |
| 200 mg, n=74, 22, 25 | 5.499 (1.449 to 12.926) | 1.583 (0.455 to 3.542) | 5.350 (3.301 to 13.750) |
| 225 mg, n=3, 0, 0 | 5.631 (4.815 to 5.642) | NA (NA to NA) | NA (NA to NA) |
| 250 mg, n=18, 11, 0 | 5.059 (2.329 to 10.969) | 4.073 (2.184 to 8.768) | NA (NA to NA) |
| 300 mg, n=193, 5, 0 | 5.493 (1.620 to 13.335) | 2.837 (1.898 to 3.558) | NA (NA to NA) |
| 350 mg, n=0, 3, 0 | NA (NA to NA) | 4.084 (3.794 to 4.165) | NA (NA to NA) |
| 400 mg, n=19, 46, 0 | 7.322 (2.899 to 13.843) | 4.012 (1.459 to 9.675) | NA (NA to NA) |
| 450 mg, n=0, 1, 0 | NA (NA to NA) | 2.975 (NA to NA) | NA (NA to NA) |
| 500 mg, n=51, 121, 0 | 6.994 (0.931 to 13.412) | 3.974 (0.905 to 11.451) | NA (NA to NA) |
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. Clearance is defined as the volume of LTG per unit time eliminated from serum. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to Clinical Pharmacokinetics Modelling and Simulation, Clinical Pharmacology, and Discovery Medicine (CPDM) by Clinical Data Management as NONMEM compatible .csv files.
| Liters per hour | LTG-XR + Neutral | LTG-XR + EIAEDs | LTG-XR + VPA |
|---|---|---|---|
| Apparent Clearance (CL/F) Based on the Concomitant AED Groups: Neutral, With EIAED, and With VPA | 1.91 (1.73 to 2.09) | 2.07 (1.69 to 2.46) | -0.698 (-0.96 to -0.441) |
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. V/F is defined as the apparent volume in which a drug is distributed immediately after it has been injected intravenously and equilibrated between plasma and the surrounding tissues. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.
| liters | LTG-XR + Neutral, EIAEDs, and VPA |
|---|---|
| Apparent Volume of Distribution (V/F) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA | 26.8 (7.40 to 46.6) |
Individual serum LTG concentration data were subjected to population pharmacokinetic methodologies based on the concomitant AED groups. KA is defined as the rate at which a drug enters the body after administration. Serum LTG concentration-time data files incorporating, where appropriate, records of LTG administration, participant demography, and concomitant medication were supplied to CPDM by Clinical Data Management as NONMEM compatible .csv files.
| 1/h | LTG-XR + Neutral, EIAEDs, and VPA |
|---|---|
| Absorption Rate (KA) for Participants in All Concomitant AED Groups Combined: Neutral, With EIAED, and With VPA | 0.0325 (0.0105 to 0.0549) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LTG-XR Tablets | — | 22/121 (18.2%) | 98/121 (81%) |
| Event | LTG-XR Tablets |
|---|---|
| Hip fractureInjury, poisoning and procedural complications | 3/121 |
| AtaxiaNervous system disorders | 2/121 |
| ConvulsionNervous system disorders | 2/121 |
| Status epilepticusNervous system disorders | 2/121 |
| Acute myocardial infarctionCardiac disorders | 1/121 |
| Balance disorderNervous system disorders | 1/121 |
| Cardiac failure congestiveCardiac disorders | 1/121 |
| Cerebrovascular accidentNervous system disorders | 1/121 |
| ColitisGastrointestinal disorders | 1/121 |
| DiverticulitisInfections and infestations | 1/121 |
| Event | LTG-XR Tablets |
|---|---|
| DizzinessNervous system disorders | 31/121 |
| Balance disorderNervous system disorders | 25/121 |
| FallInjury, poisoning and procedural complications | 22/121 |
| HeadacheNervous system disorders | 21/121 |
| TremorNervous system disorders | 20/121 |
| FatigueNervous system disorders | 17/121 |
| NauseaGastrointestinal disorders | 17/121 |
| All rashSkin and subcutaneous tissue disorders | 14/121 |
| AtaxiaNervous system disorders | 14/121 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 12/121 |
| Age, Continuous(Years) | LTG-XR Tablets |
|---|---|
| Mean | 72.5 ± 5.53 |
| Gender(Participants) | LTG-XR Tablets |
|---|---|
| Female | 59 |
| Male | 62 |
| Race/Ethnicity, Customized(participants) | LTG-XR Tablets |
|---|---|
| African American/African Heritage | 14 |
| Asian - South East Asian Heritage | 2 |
| White - Arabic/North African Heritage | 1 |
| White - White/Caucasian/European Heritage | 105 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine